 Home > Active Ingredient News > Blood System > BMJ: Heparin treatment can reduce the risk of death in hospitalized patients with moderate new coronary pneumonia with elevated D dimer levels

BMJ: Heparin treatment can reduce the risk of death in hospitalized patients with moderate new coronary pneumonia with elevated D dimer levels

 Last Update: 2021-11-03
 Source: Internet
 Author: User

Tags

hazard class 4

7 8 dhf

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The most common cause of deterioration of Covid-19 hospitalized patients with clinical illness is hypoxemia respiratory failure, pulmonary endothelial injury patients, the formation of micro- vascular thrombosis , and thus lead to coagulation disorders, the most common clinical indicators for the D- dimer levels liters High

Vascular thrombosis recently researchers examined in hospital suffering from moderate Covid-19, the therapeutic heparin and prevention of heparin therapy on the prognosis of patients

The study was carried out in 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, the United Arab Emirates and the United States.

The average age of the participants was 60 years old, 264 (56.

Four patients who received therapeutic heparin treatment died (1.

The effect of heparin treatment on the prognosis of patients

The effect of heparin treatment on the prognosis of patients The effect of heparin treatment on the prognosis of patients

The study found that in patients hospitalized with moderate Covid-19 and with elevated D-dimer levels, receiving therapeutic heparin treatment can reduce the patient's 28-day risk of death and a lower risk of bleeding

In patients hospitalized with moderate Covid-19 with elevated D-dimer levels, receiving therapeutic heparin treatment can reduce the patient’s 28-day risk of death, and the risk of bleeding is lower.

Original source:

Michelle Sholzberg et al.

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.